Results 181 to 190 of about 66,268 (303)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]

, 2016
Daisuke Koya, Keizo Kanasaki, Sen Shi
core   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4837-4846, June 2026.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects: the example of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease. [PDF]

Am J Epidemiol
Wang T, Wang J, Song Z, Miller E, Pate V, Her Q, Yang J, Charlier SHR, Egger P, Barnes EL, Buse JB, Becker C, Sandler RS, Meier C, Jick S, Stürmer T.   +15 more
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitors

Circulation Journal, 2013
openaire   +3 more sources

Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4915-4925, June 2026.
ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim   +3 more
wiley   +1 more source

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5058-5067, June 2026.
ABSTRACT Aims The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real‐world clinical settings. Materials and Methods This retrospective, multi‐centre cohort study included 195 patients with T2D initiating oral semaglutide between April 2022 and December 2023.
Taweesak Wannachalee, Pimjai Anthanont, Supamas Sirisreetreerux, Gurudutt Nayak, Woralak Chumchujan, Yodying Iamsudjai, Supawan Buranapin   +6 more
wiley   +1 more source

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

Efficacy and Safety of Automated Insulin Delivery in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5091-5100, June 2026.
ABSTRACT Aims Studies evaluating automated insulin delivery (AID) in type 2 diabetes are limited in number and often conducted in small cohorts. We aimed to summarize efficacy and safety data through a systematic review and meta‐analysis. Materials and Methods We searched MEDLINE, PubMed, Web of Science, and CENTRAL databases and performed hand ...
Sergio Di Molfetta, Ludovico Di Gioia, Irene Caruso, Mariangela Caporusso, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +7 more
wiley   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis. [PDF]

Int J Cardiol Heart Vasc
Holt MF, Michelsen AE, Flø A, Russell K, Beitnes JO, Kløve SF, Hodt A, Gullestad L, Aukrust P, Gude E, Broch K, Ueland T.   +11 more
europepmc   +1 more source

Exertional heat stress and intestinal barrier injury: Does chronic disease add fuel to the fire?

Experimental Physiology, EarlyView.
Oliver R. Gibson, Zachary J. McKenna
wiley   +1 more source